2cureX publishes the annual report for the fiscal year 2018
The Board of Directors and the CEO of 2cureX AB ("2cureX") hereby publish the annual report for the fiscal year 2018. The annual report and associated audit report are available as an attached file or on the company's website (www.2curex.com). Please note that the annual report of 2cureX is only available in Swedish.
Phone: +46 40 615 14 15
For more information about 2cureX:
Ole Thastrup, CEO
Phone: +45 22 11 53 99
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical studies are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.
The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).